Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts

Journal of Heart and Lung Transplantation

Volumn 24, Issue 4, 2005, Pages 439-445

  Lijkwan, Maarten A ^a   Cooke, David T ^b   Martens, Jasper M ^b   Kown, Murray H ^b   Murata, Seiichiro ^b   Peterson, Shannon H ^b   Hoyt, E Grant ^b   Robbins, Robert C ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOLOGIC FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CHRONIC GRAFT REJECTION; COMPREHENSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DONOR; DRUG MEGADOSE; HEART GRAFT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTIMA; INTRAOPERATIVE PERIOD; LONG TERM CARE; MACROPHAGE; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RAT; RECIPIENT; RODENT; STATISTICAL SIGNIFICANCE; TUNICA MEDIA;

EID: 15544380871     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.01.020     Document Type: Article

References (21)

1. Behrendt D., Ganz P., Fang J.C. Cardiac allograft vasculopathy. Curr Opin Cardiol. 15:2000;422-429
2. Kitagawa-Sakakida S., Tori M., Li Z., Horiguchi K., Izutani H., et al. Active cell migration in retransplanted rat cardiac allografts during the course of chronic rejection. J Heart Lung Transplant. 19:2000;584-590
3. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc. 32:(suppl 3A):2000;27S-44S
4. Mennander A., Tiisala S., Paavonen T., Halttunen J., Hayry P. Chronic rejection of rat aortic allografts. II. Administration of cyclosporine induces accelerated allograft arteriosclerosis. Transplant Int. 4:1991;173-179
5. Esper E., Glagov S., Karp R.B., et al. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation. J Heart Lung Transplant. 16:1997;420-435
6. Guttmann R.D., Forbes R.D., Zheng S., Busque S. Cyclosporine and the reversibility of chronic vascular rejection. Transplant Proc. 26:1994;2564-2566
7. Poston R.S., Billingham M., Hoyt E.G., Pollard J., Shorthouse R., Morris R.E., Robbins R.C. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 100:1999;67-74
8. Gunther E., Walter L. The major histocompatibility complex of the rat (Rattus norvegicus). Immunogenetics. 53:2001;520-542
9. Ono K., Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 57:1969;225-229
10. Hosenpud J.D., Bennett L.E., Keck B.M., Boucek M.M., Novick R.J. The registry of the International Society for Heart and Lung Transplantation eighteenth official report - 2001. J Heart Lung Transplant. 20:2001;805-815
11. Kuo P., Monaco A.P. Chronic rejection and suboptimal immunosuppression. Transplant Proc. 25:1993;2082-2084
12. Valantine H., Hunt S., Gamberg P., Miller J., Luikart H. Impact of cyclosporine dose on long-term outcome after heart transplantation. Transplant Proc. 26:1994;2710-2712
13. Gamba A., Mamprin F., Fiocchi R., et al. The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clin Cardiol. 20:1997;767-772
14. Joris I., Zand T., Nunnari J.J., Krolikowski F.J., Majno G. Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol. 113:1983;341-358
15. Ferns G., Reidy M., Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol. 137:1990;403-413
16. Fellstrom B.C., Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev. 134:1993;83-98
17. Milton A.D., Fabre J.W. Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat. J Exp Med. 161:1985;98-112
18. Halloran P.F., Urmson J., Farkas S., et al. Effects of cyclosporine on systemic MHC expression. Evidence that non-T cells produce interferon-gamma in vivo and are inhibitable by cyclosporine. Transplantation. 46:(suppl):1988;68S- 72S
19. Halloran P.F., Wadgymar A., Autenried P. Inhibition of MHC product induction may contribute to the immunosuppressive action of cyclosporine. Prog Allergy. 38:1986;258-268
20. Charreau B., Coupel S., Boulday G., Soulillou J.P. Cyclosporine inhibits class II major histocompatibility antigen presentation by xenogeneic endothelial cells to human T lymphocytes by altering expression of the class II transcriptional activator gene. Transplantation. 70:2000;354-361
21. Cotts W.G., Johnson M.R. The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev. 6:2001;227-240